NSE · INNOVACAP
Innova Captab Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹400 Cr with net profit ₹32 Cr — a 8.01% net margin, versus 8.61% the period before.
Shareholding
As of 2026-06-30
- Promoter50.9%
- Public28.84%
- FII0.34%
- DII19.92%
35,881 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #33 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,48,028 Cr | 35.46 | 5.36 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,13,227 Cr | 23.19 | 4.18 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,186 Cr | 31.07 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,258 Cr | 96.25 | 19.94 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹98,075 Cr | 30.44 | 2.57 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,239 Cr | 25.72 | 2.56 | 9.25% | 10.7% |
| Lupin Limited | ₹95,939 Cr | 16.11 | 4.26 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹95,000 Cr | 44.53 | 5.82 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,185 Cr | 21.85 | 6.48 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,949 Cr | 28.06 | 4.62 | 16.66% | 14.31% |
| Innova Captab Limited(this company) | ₹6,578 Cr | 42.7 | 6.04 | 12.92% | 8.81% |
AI analysis
AI-generated · google/gemini-2.5-flashInnova Captab Limited is listed with a market capitalization of Rs 5569 Cr. The company reported a revenue of Rs 1637.44 Cr with a profit margin of 8.65%. Its 52-week high was Rs 1034.85 and 52-week low was Rs 622.
Positives
- +Revenue grew 31.1% to Rs 1637.44 Cr.
- +Debt-to-equity ratio is 0.33, indicating a low level of debt.
- +Promoter shareholding is 50.8998%, which is over 50%.
Negatives
- −The trailing twelve months P/E ratio is 146.35, which is high.
- −FII shareholding has decreased from 1.9415% in March 2024 to 0.3383% in June 2026.
- −The dividend yield is 21%, which is significantly high and may warrant further investigation into its sustainability.
Financial Performance
Innova Captab Limited achieved a revenue of Rs 1637.44 Cr, representing a revenue growth of 31.1%. The company recorded a net profit of Rs 140.917 Cr for the fiscal year ending March 2026. Quarterly revenue for March 2026 was Rs 447.8 Cr, with a net profit of Rs 38.08 Cr.
Profitability & Returns
The company's profit margin stood at 8.65%. Return on equity (ROE) was 12.92%, and return on capital employed (ROCE) was 14.30%. Earnings per share (EPS) for the latest reported period was Rs 24.53.
Balance Sheet
Innova Captab Limited has a book value of Rs 190.61. The debt-to-equity ratio is 0.33, indicating a manageable level of debt relative to equity. No promoter shares are reported as pledged.
Ownership & Pledges
As of June 2026, promoters held 50.8998% of the shares. DIIs held 19.9199%, FIIs held 0.3383%, and the public held 28.842%. The number of shareholders was 35881. There are no reported promoter pledges.
Data as of — price: 2026-09-18 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.